Could This Medical Device Stock Be the Next Big Growth Name?

Stereotaxis is finally beginning to see revenue growth

facebook twitter linkedin


Stereotaxis, Inc. (NYSE:STXS) produces robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The medical device stock scored a seven-year high of $8.97 earlier today, and is up 75% in 2021. So given all the positive price action, the question should be for potential investors is: how much more can it climb?

There's chart support in place at STXS' 100-day moving average, which contained a pullback in May. Keep an eye on the $9 level, which is triple the shares' Nov. 6 annual lows. There isn't a lot of potential for upgrades though, considering all three brokerages rate the stock a "strong buy." 

STXS Stock Chart

During the company's earnings call to discuss the first quarter of 2021, Stereotaxis highlighted a 50% increase in revenue. STXS' revenues totaled $8.6 million at the end of the first quarter, up from $5.8 million in the prior year’s first quarter. Stereotaxis also has a great balance sheet with $44.1 million in cash and only $3.89 million in total debt, giving STXS the time and resources to continue producing and refining its technology.

However, Stereotaxis has yet to see consistent growth on the top- and bottom-lines. Between fiscal 2017 and fiscal 2020, STXS's revenues decreased by more than 14%. It has only been in the past 12 months that the company has seen a 10.7% growth in revenues. Overall, the company’s balance sheet places it in a good position to expand the business substantially, but it will be vital for Stereotaxis to begin seeing consistent revenue growth before investors can wisely jump into the investment.

Make the Most of the next Expiration Week Countdown!


 




 
Special Offers from Schaeffer's Trading Partners